MENU
+Compare
ZLAB
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$26.05
Change
+$0.67 (+2.64%)
Capitalization
2.85B

ZLAB Zai Lab Limited Forecast, Technical & Fundamental Analysis

a service for cancer & autoimmune treatment

Industry Biotechnology
ZLAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ZLAB with price predictions
Jan 14, 2025

ZLAB's Stochastic Oscillator remains in oversold zone for 1 day

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ZLAB advanced for three days, in of 290 cases, the price rose further within the following month. The odds of a continued upward trend are .

ZLAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 02, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ZLAB as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZLAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ZLAB entered a downward trend on January 14, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ZLAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.250) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (87.786). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.852). ZLAB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (7.143) is also within normal values, averaging (263.573).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZLAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ZLAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ZLAB is expected to report earnings to rise 1,724.25% to -72 cents per share on March 04

Zai Lab Limited ZLAB Stock Earnings Reports
Q4'24
Est.
$-0.73
Q3'24
Beat
by $0.73
Q2'24
Missed
by $0.11
Q1'24
Beat
by $0.88
Q4'23
Missed
by $0.77
The last earnings report on November 12 showed earnings per share of -3 cents, beating the estimate of -76 cents. With 720.33K shares outstanding, the current market capitalization sits at 2.85B.
A.I. Advisor
published General Information

General Information

a service for cancer & autoimmune treatment

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
4560 Jinke Road
Phone
+86 2161632588
Employees
2175
Web
https://www.zailaboratory.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
BTC.X104408.070000-53.968750
-0.05%
Bitcoin cryptocurrency
GME27.51-0.21
-0.76%
GameStop Corp

ZLAB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ZLAB has been loosely correlated with ADPT. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLAB jumps, then ADPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZLAB
1D Price
Change %
ZLAB100%
+2.64%
ADPT - ZLAB
37%
Loosely correlated
-1.59%
VERV - ZLAB
33%
Poorly correlated
+0.66%
CRSP - ZLAB
32%
Poorly correlated
+0.57%
PRME - ZLAB
32%
Poorly correlated
+0.70%
EDIT - ZLAB
31%
Poorly correlated
-1.61%
More